Nyxoah (NASDAQ:NYXH) Announces Earnings Results

Nyxoah (NASDAQ:NYXH) released its earnings results on Thursday. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.03), Zacks reports. The business had revenue of $1.35 million for the quarter, compared to analyst estimates of $2.02 million. Nyxoah had a negative return on equity of 51.68% and a negative net margin of 1,043.93%.

Nyxoah Price Performance

Shares of NYXH stock opened at $10.51 on Friday. The company has a quick ratio of 4.95, a current ratio of 5.28 and a debt-to-equity ratio of 0.21. Nyxoah has a 12-month low of $6.76 and a 12-month high of $20.00. The firm has a fifty day moving average of $10.29 and a 200-day moving average of $9.18. The firm has a market capitalization of $357.97 million, a price-to-earnings ratio of -5.62 and a beta of 1.42.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on NYXH. HC Wainwright reaffirmed a “buy” rating and set a $17.00 price objective on shares of Nyxoah in a research note on Friday, December 13th. Stifel Nicolaus decreased their target price on Nyxoah from $16.00 to $15.00 and set a “buy” rating for the company in a research report on Friday.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.